Sublingual apomorphine as a neuroendocrine probe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43902509" target="_blank" >RIV/00216208:11120/12:43902509 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/12:10133292 RIV/00023752:_____/12:43913801

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.psychres.2011.09.022" target="_blank" >http://dx.doi.org/10.1016/j.psychres.2011.09.022</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.psychres.2011.09.022" target="_blank" >10.1016/j.psychres.2011.09.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sublingual apomorphine as a neuroendocrine probe

Popis výsledku v původním jazyce

Subcutaneous apomorphine, a dopaminergic agonist, is used as a neuroendocrine probe for assessing central dopaminergic activity. The aim of our study was to test sublingual apomorphine for the same purpose. We administered sublingual apomorphine in a weight-dependent dose (0.033mg/kg) to 42 healthy men. Prolactin and growth hormone levels were measured before and after the administration at 15, 30, 45, 60, 75, 90, 120, 150 and 180min. Subjects filled in Zung's self-assessment scores of anxiety (SAS) anddepression (SDS) questionnaires before and after the test. Areas under the curve for prolactin and growth hormone levels were calculated using the trapezoidal rule. All subjects showed decreased prolactin, and 40/42 subjects showed increased growth hormone, in response to sublingual apomorphine. Average peak value for prolactin was -4.6?1.8?g/l. Average peak value for growth hormone was 8.1?8.5ng/ml for the whole group, and 9.6?8.1ng/ml after exclusion of two negative growth hormone res

Název v anglickém jazyce

Sublingual apomorphine as a neuroendocrine probe

Popis výsledku anglicky

Subcutaneous apomorphine, a dopaminergic agonist, is used as a neuroendocrine probe for assessing central dopaminergic activity. The aim of our study was to test sublingual apomorphine for the same purpose. We administered sublingual apomorphine in a weight-dependent dose (0.033mg/kg) to 42 healthy men. Prolactin and growth hormone levels were measured before and after the administration at 15, 30, 45, 60, 75, 90, 120, 150 and 180min. Subjects filled in Zung's self-assessment scores of anxiety (SAS) anddepression (SDS) questionnaires before and after the test. Areas under the curve for prolactin and growth hormone levels were calculated using the trapezoidal rule. All subjects showed decreased prolactin, and 40/42 subjects showed increased growth hormone, in response to sublingual apomorphine. Average peak value for prolactin was -4.6?1.8?g/l. Average peak value for growth hormone was 8.1?8.5ng/ml for the whole group, and 9.6?8.1ng/ml after exclusion of two negative growth hormone res

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Psychiatry Research

ISSN

0165-1781

e-ISSN

—

Svazek periodika

198

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

3

Strana od-do

297-299

Kód UT WoS článku

000311987000021

EID výsledku v databázi Scopus

—